Currently out of the existing stock ratings of Gil Blum, 176 are a BUY (98.32%), 3 are a HOLD (1.68%).

Gil Blum

Work Performance Price Targets & Ratings Chart

Analyst Gil Blum works at NEEDHAM with a stock forecast success ratio of 25.95% fulfilled within 107.87 days on average. Previously, Gil Blum worked at TRUIST.

Gil Blum’s has documented 356 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NRIX, Nurix Therapeutics at 02-Apr-2024.

Wall Street Analyst Gil Blum

Analyst best performing recommendations are on NKTX (NKARTA ).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 10/31/2023. The price target of $82 was fulfilled within 7 days with a profit of $14.69 (21.82%) receiving and performance score of 31.18.

Average potential price target upside

of $51.56 (63.45%) on SRPT (SAREPTA THERAPEUTICS).
of $30.3 (57.28%) on CRSP (CRISPR THERAPEUTICS AG).
of $11.03 (29.37%) on ACLX (ARCELLX).

AVRO AVROBIO GBIO Generation Bio Co TSHA Taysha Gene Therapies FOLD Amicus Therapeutics AUTL Autolus Therapeutics Ltd RCKT Rocket Pharmaceuticals SRPT Sarepta Therapeutics AGLE Aeglea Bio Therapeutics GTHX G1 Therapeutics NRIX Nurix Therapeutics NXTC NextCure MREO Mereo BioPharma Group PLC ADR IMAB I-Mab SELB Selecta Biosciences STTK Shattuck Labs GMDA Gamida Cell Ltd CTIC CTi Biopharma Corp ACLX Arcellx GERN Geron CELC Celcuity LLC CRSP Crispr Therapeutics AG NKTX Nkarta RXRX Recursion Pharmaceuticals IMCR Immunocore Holdings Ltd

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Uy Ear (MIZUHO)